An update on the chemistry and medicinal chemistry of novel antimycobacterial compounds.
Tuberculosis (TB) is a serious public health issue, particularly in underdeveloped and developing countries. Furthermore the first-line anti-TB treatments were established over 40 years ago, multidrug-resistant Mycobacterium tuberculosis strains have been developed and the risk of coinfection with AIDS virus has highlighted this disease as a global emergency. The urgent need for more effective treatments against multidrug-resistant strains compatible with anti-AIDS drugs has prompted industries, governments and non-governmental agencies to pursue new drugs. In this study, we update the portfolio listed at Stop TB Partnership, present the biological activities as well as structure-activity relationship for these drugs and thoroughly discuss the synthetic methodologies used to produce these drugs.